1. 要旨
2. 分類学と市場定義を含む業界紹介
3. マクロ経済要因、市場ダイナミクス、最近の業界動向など、世界市場の動向と成功要因
4. 歴史分析と将来予測を含む、世界市場の需要分析2019年～2023年および予測2024年～2034年
5. 世界市場の分析 2019～2023年および2024～2034年予測
5.1. 治療タイプ
5.2. 投与経路
5.3. 治療モード
5.4. 年齢層
5.5. エンドユーザー
6. 世界市場分析2019〜2023年および予測2024〜2034年：治療タイプ別
6.1. 化学療法
6.2. 標的療法
6.3. 免疫療法
6.4. 放射線療法
6.5. 併用療法
7. 投与経路別の世界市場分析2019～2023年および予測2024～2034年
7.1. 経口
7.2. 静脈内投与
8. 治療モード別の世界市場分析2019～2023年および予測2024～2034年
8.1. 単回投与
8.2. 多剤投与
9. 世界市場分析2019～2023年および予測2024～2034年：年齢層別
9.1. 小児
9.2. 大人
9.3. 老人
9.4. 地域／専門クリニック
10. 世界市場分析2019～2023年および予測2024～2034年：エンドユーザー別
10.1. 病院
10.2. 専門クリニック
10.3. 外来手術センター
10.4. リハビリケア
11. 世界市場分析2019～2023年および予測2024～2034年、地域別
11.1. 北米
11.2. 中南アメリカ
11.3. 西ヨーロッパ
11.4. 東欧
11.5.
東アジア
11.6.
南アジア・太平洋
11.7.
MEA
12. 北米の主要セグメント・国別売上高分析 2019～2023年および予測 2024～2034年
13.中南アメリカ売上高分析 2019～2023年および2024～2034年予測：主要セグメント・国別
14.西欧売上高分析 2019～2023年および2024～2034年予測：主要セグメント・国別
15.東欧売上高分析 2019～2023年および2024～2034年予測：主要セグメント・国別
16.東アジアの売上高分析 2019～2023年および2024～2034年予測：主要セグメント・国別
17.南アジア・太平洋地域 売上高分析 2019～2023年および2024～2034年予測：主要セグメント・国別
18.MEA売上高分析 2019～2023年および2024～2034年予測：主要セグメント別、国別
19.2024～2034年までの売上高予測：30ヵ国：治療タイプ、投与経路、治療モード、年齢層、エンドユーザー別
20.市場構造分析、主要企業別シェア分析、競争ダッシュボードを含む競争展望
21. 企業プロフィール
21.1. Pfizer
21.2. Sanofi
21.3. Taiho Pharma
21.4. Ono Pharma
21.5. Hutchison Medipharma
21.6. Isofol Medical
21.7. Sumitomo Dainippon Pharma
21.8. G1 Therapeutics
21.9. Merck & co
21.10. Bristol-Myers Squibb Co
21.11. Daiichi Sankyo/Astrazeneca
21.12. Eli Lilly and Company
21.13. Mirati Therapeutics
21.14. Cardiff Oncology
21.15. Abbott Laboratories
21.16. Epigenomics AG.
22. Assumptions & Acronyms Used
23. Research Methodology & Data Sources
Metastatic Colorectal Cancer Market - Scope of ReportA recent study by Fact.MR on the metastatic colorectal cancer market offers a 10-year forecast for 2024 to 2034. The study analyzes crucial trends that are currently determining the growth of the market. This report explicates on vital dynamics, such as the drivers, restraints, and opportunities for key market players along with key stakeholders as well as emerging players associated with offering metastatic colorectal cancer.
The study also provides the dynamics responsible for influencing the future status of the metastatic colorectal cancer market over the forecast period. A detailed assessment of value chain analysis, business execution, and supply chain analysis across regional markets has been covered in the report.
A list of prominent companies operating in the metastatic colorectal cancer market, along with their product portfolios, key strategies and SWOT analysis, enhances the reliability of this comprehensive research study.
Report Summary
The study offers comprehensive analysis on diverse features, including production capacities, demand, product developments, revenue generation, and sales of metastatic colorectal cancer across the globe.
A comprehensive estimate on the market has been provided through an optimistic as well as a conservative scenario, taking into account the sales of metastatic colorectal cancer during the forecast period. Price point comparison by region with global average price is also considered in the study.
Analysis on Market Size Evaluation
The market has been analyzed for each segment in terms of value (US$ Mn).
Estimates at global and regional levels for metastatic colorectal cancer are available in terms of “US$ Mn” for value. A Y-o-Y growth contrast on prominent market segments, along with market attractiveness evaluation, has been incorporated in the report. Furthermore, absolute dollar opportunity analysis of all the segments adds prominence to the report.
Absolute dollar opportunity plays a crucial role in assessing the level of opportunity that a manufacturer/distributor can look to achieve, along with identifying potential resources, considering the sales and distribution perspective in the global metastatic colorectal cancer market.
Inspected Assessment on Regional Segments
Key sections have been elaborated in the report, which have helped deliver projections on regional markets. These chapters include regional macros (political, economic, and business environment outlook), which are expected to have a momentous influence on the growth of the metastatic colorectal cancer market during the forecast period.
Country-specific valuation on demand for metastatic colorectal cancer has been offered for each region, along with market scope estimates and forecasts, price index, and impact analysis of the dynamics of prominence in regions and countries. For all regional markets, Y-o-Y growth estimates have also been incorporated in the report.
Detailed breakup in terms of value & volume for emerging countries has also been included in the report.
In-depth Analysis on Competition
The report sheds light on leading manufacturers of metastatic colorectal cancer, along with their detailed profiles. Essential and up-to-date data related to market performers who are principally engaged in offering metastatic colorectal cancer has been brought with the help of a detailed dashboard view. Market share analysis and comparison of prominent players provided in the report permits report readers to take preemptive steps in advancing their businesses.
Company profiles have been included in the report, which include essentials such as product portfolios and key strategies, along with all-inclusive SWOT analysis on each player. Company presence is mapped and presented through a matrix for all the prominent players, thus providing readers with actionable insights, which helps in thoughtfully presenting the market status, and predicting the competition level in the metastatic colorectal cancer domain.
1. Executive Summary
2. Industry Introduction, Including Taxonomy and Market Definition
3. Global Market Trends and Success Factors, Including Macro-economic Factors, Market Dynamics, and Recent Industry Developments
4. Global Market Demand Analysis 2019 to 2023 and Forecast 2024 to 2034, Including Historical Analysis and Future Projections
5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034
5.1. Treatment Type
5.2. Route of Administration
5.3. Therapy Mode
5.4. Age Group
5.5. End User
6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Treatment Type
6.1. Chemotherapy
6.2. Targeted Therapy
6.3. Immunotherapy
6.4. Radiotherapy
6.5. Combination Therapy
7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Route of Administration
7.1. Oral
7.2. Intravenous
8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Therapy Mode
8.1. Single Dose Administration
8.2. Multi Dose Administration
9. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Age Group
9.1. Children
9.2. Adults
9.3. Geriatric
9.4. Community/Specialty Clinics
10. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By End User
10.1. Hospitals
10.2. Specialty Clinics
10.3. Ambulatory Surgical Centers
10.4. Rehab Care
11. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region
11.1. North America
11.2. Latin America
11.3. Western Europe
11.4. Eastern Europe
11.5. East Asia
11.6. South Asia & Pacific
11.7. MEA
12. North America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
13. Latin America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
14. Western Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
15. Eastern Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
16. East Asia Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
17. South Asia & Pacific Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
18. MEA Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
19. Sales Forecast 2024 to 2034 by Treatment Type, Route of Administration, Therapy Mode, Age Group, and End User for 30 Countries
20. Competition Outlook, Including Market Structure Analysis, Company Share Analysis by Key Players, and Competition Dashboard
21. Company Profile
21.1. Pfizer
21.2. Sanofi
21.3. Taiho Pharma
21.4. Ono Pharma
21.5. Hutchison Medipharma
21.6. Isofol Medical
21.7. Sumitomo Dainippon Pharma
21.8. G1 Therapeutics
21.9. Merck & co
21.10. Bristol-Myers Squibb Co
21.11. Daiichi Sankyo/Astrazeneca
21.12. Eli Lilly and Company
21.13. Mirati Therapeutics
21.14. Cardiff Oncology
21.15. Abbott Laboratories
21.16. Epigenomics AG.
22. Assumptions & Acronyms Used
23. Research Methodology & Data Sources
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
